The Weekly Roundup: June 9-13

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria

The monoclonal anti-KIT antibody exhibited promise in adults with moderate to severe antihistamine-refractory CSU.

Almirall Is First to Apply WHO-5 Well-Being Index in Dermatological Clinical Trial End Points

Almirall is pioneering a holistic approach in dermatology, emphasizing psychological well-being through the WHO-5 index in clinical trials.

Hydrafacial Launches HydraFillic 9-Peptide Booster for Advanced Skin Rejuvenation

Discover the revolutionary Hydrafacial HydraFillic with Pep9 Booster, enhancing skin hydration and reducing fine lines with advanced peptide technology.

Continuous Treatment With Rupatadine Shows Real-World Efficacy in Chronic Spontaneous Urticaria

Treatment with rupatadine led to improvements in CSU and chronic inducible urticaria.

RAD 2025 Poster Highlights Ruxolitinib Cream Safety in Combination AD Regimens

Recent research presented at the 2025 RAD Meeting explored the use of ruxolitinib cream in combination with systemic therapy.

Chronic Urticaria Is Linked to Increased Odds of Psychiatric Comorbidity

Researchers found CU was associated with increased odds of developing anxiety, depression, PTSD, and substance use disorder, among other conditions.

Late-Breaking Data: Flexible Dosing of Abrocitinib for AD Shows Real-World Promise

The JADE REAL study reported that flexible dosing of abrocitinib exhibited promise in patients with moderate to severe AD.

Late Breaking Data: Long-Term Safety and Efficacy of Nemolizumab for AD

Galderma unveils promising long-term data on nemolizumab for atopic dermatitis, showcasing significant skin improvement and quality of life enhancements.

OX40/OX40L Inhibitors Offer Upstream Signaling Pathways in Atopic Dermatitis

At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.

Journal Digest: June 11, 2025

This review of the latest dermatologic studies includes insights into skin improvement with injectable hyaluronic acid, burden of chronic spontaneous urticaria, and more.

Challenges and Emerging Therapies in CHE: Insights from Fall Clinical PA/NP 2025

At the Fall Clinical PA/NP 2025 Conference, attendees caught up on the ins and outs of CHE.

Three-Year Data Reveals Long-Term Power of Bimekizumab for PsA

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.

Why Plant-Derived Exosomes are Revolutionizing Regenerative Skin Care, According to Frank Roesken, MD, PhD

Discover the future of regenerative skincare with Skin Moderne’s groundbreaking Exosomes Regenerative Complex, a plant-derived innovation led by Dr. Frank Roesken, MD, PhD.

Guselkumab Effectively Inhibits Joint Structural Damage in Active PsA

Data presented at EULAR 2025 showcased Tremfya's efficacy as the only IL-23 inhibitor to demonstrate inhibition of this nature in psoriatic arthritis.

Late-Breaking Data: Positive Outcomes in AD Patients with Skin of Color Using Dupilumab

At RAD 2025, the DISCOVER trial showed that dupilumab monotherapy significantly improved moderate to severe AD symptoms in this patient population.

Differentiating IL-31 and IL-13 Inhibition in Atopic Dermatitis

At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.

Diagnosing and Managing GPP: Top Insights From the Experts

Aaron Farberg, MD, led a panel exploring the challenges of diagnosing and treating generalized pustular psoriasis and the promise of targeted therapies.

Alys Pharmaceuticals Submits ALY-301 Clinical Trial Application in Germany for Cold Urticaria

Alys plans to conduct a phase 1/1b trial assessing the efficacy and safety of the mast cell selective c-Kit inhibitor in the CIndU subtype.

Five Clinical Subtypes Identified in Vitiligo Cohort

Recent research outlined 5 subtypes of vitiligo that can be used to guide therapeutic choices.

Clinical Pearls from the 2025 Fall Clinical PA/NP Meeting: Day 1

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the first day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Novel Stem Hair Serum Improves Hair Loss When Combined with Minoxidil

In a real-world study, the combination of Cuticapil stem hair serum and minoxidil reduced shedding and improved hair density.

It's Not Genital Warts: A Clinician's Guide to Reassuring Men's Genital Concerns

In celebration of Men's Health Month, Hershel Dobkin, MD, FAAD, shed some light on a "taboo" topic.

A Clinician’s Perspective of RAD 2025: Part 1

Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

At-Home Facial Massage Methods Clinically Proven to Improve Skin Elasticity, Tone, and Contour

A new comparative study evaluated positive outcomes from patient use of a gua sha versus a facial roller over 8 weeks of treatment.

The Broader Spectrum of Sun Damage and Skin Protection

Susan Taylor, MD, FAAD, provided valuable insights into the complex nature of sun protection in a recent Dermatology Times DermView custom video series.

Adam Friedman, MD, FAAD: Healing Spaces and Holistic HS Care

Adam Friedman, MD, FAAD, discusses the growing need for psychosocial support in hidradenitis suppurativa care and HS Connect’s role in closing the gap.